Back to top
more

Repligen (RGEN)

(Delayed Data from NSDQ)

$116.50 USD

116.50
754,697

-2.41 (-2.03%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $116.50 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Here's Why Repligen (RGEN) is a Great Momentum Stock to Buy

by Zacks Equity Research

Does Repligen (RGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

Is Repligen (RGEN) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (RGEN) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Repligen (RGEN) Beats on Q3 Earnings, Lifts 2019 Guidance

by Zacks Equity Research

Repligen (RGEN) rides high on earnings and revenue beat in the third quarter of 2019. The company also raises 2019 guidance.

Zacks Equity Research

Repligen (RGEN) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Repligen (RGEN) delivered earnings and revenue surprises of 30.00% and 5.06%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Repligen (RGEN) Reports Next Week: What to Expect

by Zacks Equity Research

Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?

by Zacks Equity Research

Sector ETF report for PSCH

Zacks Equity Research

Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?

by Zacks Equity Research

Sector ETF report for PSCH

Sweta Killa headshot

Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?

by Sweta Killa

Sector ETF report for PSCH

Zacks Equity Research

Blueprint Medicines (BPMC) Q2 Loss Widens, Sales Top Mark

by Zacks Equity Research

Blueprint Medicines (BPMC) suffers wider-than-expected loss in the second quarter while sales beat estimates.

Zacks Equity Research

Acorda (ACOR) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Acorda (ACOR) posts narrower-than-expected loss while revenues top estimates in the second quarter. Inbrija delivers a solid start with sales rising sequentially.

Zacks Equity Research

Agios' (AGIO) Loss Widens in Q2, Tibsovo Drives Sales

by Zacks Equity Research

Agios (AGIO) incurs wider-than-expected loss in Q2 while revenues beat estimates. The company's newly approved leukemia drug Tibsovo sees a rise in sales sequentially.

Zacks Equity Research

Vertex (VRTX) Beats on Q2 Earnings, Ups CF Product Sales View

by Zacks Equity Research

Vertex (VRTX) beats on earnings and sales in second-quarter 2019. The company lifts its full-year revenue guidance, led by a solid CF products' performance, especially Symdeko.

Zacks Equity Research

Repligen (RGEN) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Repligen (RGEN) delivered earnings and revenue surprises of 24.00% and 10.10%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Nalak Das headshot

Powell Gives Space for Growth, Market Overreacts: 5 Picks

by Nalak Das

Although market participants were expecting a quarter percentage point of cut, they were taken aback by Fed Chair Jerome Powell's comment that this rate cut is "in the nature of a mid-cycle adjustment to policy."

Zacks Equity Research

The Zacks Analyst Blog Highlights: Repligen, Tandem Diabetes Care, Telephone and Data Systems, Sunoco and Rent-A-Center

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Repligen, Tandem Diabetes Care, Telephone and Data Systems, Sunoco and Rent-A-Center

Nalak Das headshot

5 Top Picks on Three Key Takeaways From Q2 U.S. GDP

by Nalak Das

A closer look at the second-quarter GDP will help us to make three important inferences, which are expected to give guidance on the economy and stock market in the near term.

Zacks Equity Research

Medicines Company (MDCO) Q2 Earnings Top, Inclisiran in View

by Zacks Equity Research

The Medicines Company (MDCO) posts narrower-than-expected loss in Q2. The company did not generate any revenues in the period while its focus is steady on its sole pipeline candidate, inclisiran.

Zacks Equity Research

Repligen (RGEN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Repligen (RGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Is a Beat in Store for Repligen (RGEN) This Earnings Season?

by Zacks Equity Research

On Repligen's (RGEN) second-quarter earnings call, investor focus will be on its advancement with the proposed acquisition of C Technologies, Inc.

Zacks Equity Research

Is Repligen (RGEN) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (RGEN) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

NuCana Initiates Dosing in Phase I Study for Solid Tumors

by Zacks Equity Research

NuCana (NCNA) doses the first patient in a phase I study on NUC-7738, which is being evaluated for the treatment of advanced solid tumors.

Zacks Equity Research

Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?

by Zacks Equity Research

Sector ETF report for PSCH

Zacks Equity Research

Inovio Ends Enrollment in Vulvar Dysplasia Study on VGX-3100

by Zacks Equity Research

Inovio (INO) closes enrollment in the phase II study, evaluating VGX-3100 for the treatment of HPV-related vulvar dysplasia.

Zacks Equity Research

Here is Why Growth Investors Should Buy Repligen (RGEN) Now

by Zacks Equity Research

Repligen (RGEN) could produce exceptional returns because of its solid growth attributes.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Core-Mark, Repligen, Aaron's, HubSpot and Quanex Building Products

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Core-Mark, Repligen, Aaron's, HubSpot and Quanex Building Products